Trial reportThe journal of spinal cord medicine2026
Tailored transcutaneous electrical nerve stimulation improves dysesthesia in individuals with spinal cord injury: A randomized N-of-1 trial.
Trial report in The journal of spinal cord medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immediate changes during dysesthesia-matched transcutaneous electrical nerve stimulation in refractory neuropathic pain: a retrospective observational case series.Journal of neuroengineering and rehabilitation · 2026Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextCurrent therapeutic interventions are often ineffective for dysesthesia, including tingling and allodynia, caused by spinal cord injury (SCI). Dysesthesia-matched TENS (DM-TENS) is an innovative approach for dysesthesias that customizes stimulation parameters to align with an individual's specific dysesthesia characteristics.
objectiveWe aimed to evaluate the efficacy of DM-TENS for dysesthesia in individuals with SCI.
designA randomized, placebo-controlled, aggregated N-of-1 trial was conducted in six individuals with SCI.
methodsParticipants received either DM-TENS as an intervention or sham TENS as a control. Each treatment was administered for 60 min/day over a 7-day period. The outcome measures included the Numeric Rating Scale (NRS) for dysesthesia and Short-Form McGill Pain Questionnaire-2 (SF-MPQ2).
resultsUsing a hierarchical Bayesian model, we found that dysesthesia-matched TENS provided clinically meaningful improvements in dysesthesia among individuals with SCI, with a high posterior probability (96-100%) exceeding the minimal clinically meaningful difference (NRS of 2.70) at both the individual and population levels. The mean NRS was 5.79 (95% credible interval [95% CI]: 4.58-7.01) during the placebo period, and 1.12 (95% CI: 0.59-1.66) during the DM-TENS period. In the SF-MPQ-2, the dysesthesia-matched TENS effects showed decisive evidence (BF
conclusionsThis series of N-of-1 trials comparing dysesthesia-matched TENS with placebo indicated a reduction in dysesthesia in individuals with SCI. Thus, dysesthesia-matched TENS is a promising therapeutic option for managing dysesthesia in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.